This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burton, E. C. Articles by Aldape, K. D. Search for Related Content PubMed PubMed Citation Articles by Burton, E. C. Articles by Aldape, K. D.

Genetic Aberrations Defined by Comparative Genomic Hybridization Distinguish Long-Term from Typical Survivors of Glioblastoma¹

Departments of Laboratory Medicine [B. G. F.] and Neurological Surgery [E. C. B., K. R. L., B. G. F., M. P.], University of California, San Francisco, California 94143; Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [K. D. A.]; Department of Medicine, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, 2N4N2 Canada [J. S., P. F.]; and Department of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota 55905 [S. P., R. B. J.]

Glioblastoma (GBM) remains a highly lethal neoplasm, refractory to current therapies. The molecular genetic aberrations most closely related to clinical aggressiveness in GBM have been difficult to identify, perhaps due in part to the short survival range observed in cohorts of GBM patients. To address this, we characterized 39 tumors from rare patients (2–5% of all GBM cases) who experienced long-term survival (>3 years) using comparative genomic hybridization as a genome-wide screen. We then compared the frequency and type of aberrations with those in tumors from 24 typical or short-term survivors [STSs (<1.5 years)]. Losses of 9p and 10 and simple gains of chromosome 7 showed at least trends toward increased frequency in the STS group. Additional aberrations, including loss of 6q and gains of 19q and 20q, were significantly more frequent in the STS group. The presence of 19q loss was exclusive to the long-term survivor (LTS) group. Multivariate analyses indicated that 6q loss, 10q loss, and 19q gain were associated with short-term survival (all P < 0.01). The combination of any two of these three aberrations was seen in 16 of 24 STSs but only 1 of 39 LTSs. This comparison of rare LTSs with STSs (typical GBM survivors) identified 6q loss, 10q loss, and 19q gain, particularly when two or more of these were present, as most closely associated with aggressive clinical behavior in GBM. Loss of 19q may be a marker of long-term survival.

This article has been cited by other articles:

				H. Colman, L. Zhang, E. P. Sulman, J. M. McDonald, N. L. Shooshtari, A. Rivera, S. Popoff, C. L. Nutt, D. N. Louis, J. G. Cairncross, et al. A multigene predictor of outcome in glioblastoma Neuro Oncology, October 20, 2009; (2009) nop007v1. [Abstract] [Full Text] [PDF]

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al. Long-term survival with glioblastoma multiforme Brain, October 1, 2007; 130(10): 2596 - 2606. [Abstract] [Full Text] [PDF]

				W. F Zeng, K. Navaratne, R. A Prayson, and R. J Weil Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme J. Clin. Pathol., February 1, 2007; 60(2): 218 - 221. [Abstract] [Full Text] [PDF]

				E. A. Maher, C. Brennan, P. Y. Wen, L. Durso, K. L. Ligon, A. Richardson, D. Khatry, B. Feng, R. Sinha, D. N. Louis, et al. Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities Cancer Res., December 1, 2006; 66(23): 11502 - 11513. [Abstract] [Full Text] [PDF]

				J. P. Steinbach, H. -P. Blaicher, U. Herrlinger, W. Wick, T. Nagele, R. Meyermann, M. Tatagiba, M. Bamberg, J. Dichgans, H. -O. Karnath, et al. Surviving glioblastoma for more than 5 years: The patient's perspective Neurology, January 24, 2006; 66(2): 239 - 242. [Abstract] [Full Text] [PDF]

				A. B.Y. Hui, H. Takano, K.-W. Lo, W.-L. Kuo, C. N.Y. Lam, C. Y.K. Tong, Q. Chang, J. W. Gray, and H.-K. Ng Identification of a Novel Homozygous Deletion Region at 6q23.1 in Medulloblastomas Using High-Resolution Array Comparative Genomic Hybridization Analysis Clin. Cancer Res., July 1, 2005; 11(13): 4707 - 4716. [Abstract] [Full Text] [PDF]

				J. Vandesompele, M. Baudis, K. De Preter, N. Van Roy, P. Ambros, N. Bown, C. Brinkschmidt, H. Christiansen, V. Combaret, M. Lastowska, et al. Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma J. Clin. Oncol., April 1, 2005; 23(10): 2280 - 2299. [Abstract] [Full Text] [PDF]

				J. M. Nigro, A. Misra, L. Zhang, I. Smirnov, H. Colman, C. Griffin, N. Ozburn, M. Chen, E. Pan, D. Koul, et al. Integrated Array-Comparative Genomic Hybridization and Expression Array Profiles Identify Clinically Relevant Molecular Subtypes of Glioblastoma Cancer Res., March 1, 2005; 65(5): 1678 - 1686. [Abstract] [Full Text] [PDF]

				A. Korshunov, R. Sycheva, and A. Golanov Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization Clin. Cancer Res., December 1, 2004; 10(23): 7820 - 7826. [Abstract] [Full Text] [PDF]

				M. S. Bobola, M. J. Emond, A. Blank, E. H. Meade, D. D. Kolstoe, M. S. Berger, R. C. Rostomily, D. L. Silbergeld, A. M. Spence, and J. R. Silber Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy Clin. Cancer Res., December 1, 2004; 10(23): 7875 - 7883. [Abstract] [Full Text] [PDF]

				R. N. Wiltshire, J. E. Herndon II, A. Lloyd, H. S. Friedman, D. D. Bigner, S. H. Bigner, and R. E. McLendon Comparative Genomic Hybridization Analysis of Astrocytomas: Prognostic and Diagnostic Implications J. Mol. Diagn., August 1, 2004; 6(3): 166 - 179. [Abstract] [Full Text]

				J. F. Megyesi, E. Kachur, D. H. Lee, M. C. Zlatescu, R. A. Betensky, P. A. Forsyth, Y. Okada, H. Sasaki, M. Mizoguchi, D. N. Louis, et al. Imaging Correlates of Molecular Signatures in Oligodendrogliomas Clin. Cancer Res., July 1, 2004; 10(13): 4303 - 4306. [Abstract] [Full Text] [PDF]

				D. J. Brat, W. F. Seiferheld, A. Perry, E. H. Hammond, K. J. Murray, A. R. Schulsinger, M. P. Mehta, and W. J. Curran Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials Neuro-oncol, April 1, 2004; 6(2): 96 - 103. [Abstract] [PDF]